modimelanotide

Modimelanotide is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH). It was developed as a non-selective agonist of melanocortin receptors, with high affinity for MC1, MC3, MC4, and MC5 receptors (IC50 values of 2.9 nM for MC1, 1.9 nM for MC3, 3.7 nM for MC4, and 110 nM for MC5). The drug was investigated primarily for the prevention and treatment of acute kidney injury in patients undergoing high-risk surgeries such as cardiopulmonary bypass. Despite promising preclinical results and some early clinical efficacy signals in reducing acute kidney injury incidence after surgery, modimelanotide failed to demonstrate significant benefit in later-stage clinical trials using both traditional and novel biomarkers of renal injury. As a result, its development was discontinued[1][3][4].

Other names

Acetylhexa-L-lysyl-α-MSH